Clinical Trial Update: Safety, Tolerability, and Immunogenicity of ALFQ in a HIV Vaccine Containing A244 and B.65321 in Healthy Adults [Phase 1]

View source ↗

Summary

Phase 1 trial assessing safety, tolerability, and immunogenicity of an ALFQ-adjuvanted HIV vaccine containing A244 and B.65321 in healthy adults; the study has …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Immunodeficiency Syndrome
• HIV Infection

Drugs mentioned

• A244 (A244)
• ALFQ (Adjuvant Lipid Formulation with QS-21)
• B.65321 (B.65321)

Snippet

Sponsor: U.S. Army Medical Research and Development Command | Conditions: Human Immunodeficiency Virus (HIV), AIDS Virus | Phase 1 | Status: COMPLETED